198 related articles for article (PubMed ID: 27310704)
1. Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.
Cha Y; Kim KJ; Han SW; Rhee YY; Bae JM; Wen X; Cho NY; Lee DW; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Kang GH; Kim TY
Br J Cancer; 2016 Jul; 115(2):164-71. PubMed ID: 27310704
[TBL] [Abstract][Full Text] [Related]
2. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
3. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Ogino S; Meyerhardt JA; Kawasaki T; Clark JW; Ryan DP; Kulke MH; Enzinger PC; Wolpin BM; Loda M; Fuchs CS
Virchows Arch; 2007 May; 450(5):529-37. PubMed ID: 17372756
[TBL] [Abstract][Full Text] [Related]
4. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
Ogino S; Kawasaki T; Kirkner GJ; Ohnishi M; Fuchs CS
BMC Cancer; 2007 May; 7():72. PubMed ID: 17474983
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
[TBL] [Abstract][Full Text] [Related]
6. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Zhang X; Shimodaira H; Soeda H; Komine K; Takahashi H; Ouchi K; Inoue M; Takahashi M; Takahashi S; Ishioka C
Int J Clin Oncol; 2016 Dec; 21(6):1091-1101. PubMed ID: 27435270
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.
Ogino S; Kawasaki T; Kirkner GJ; Kraft P; Loda M; Fuchs CS
J Mol Diagn; 2007 Jul; 9(3):305-14. PubMed ID: 17591929
[TBL] [Abstract][Full Text] [Related]
8. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
[TBL] [Abstract][Full Text] [Related]
9. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
[TBL] [Abstract][Full Text] [Related]
10. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Suemoto Y; Meyerhardt JA; Fuchs CS
Gut; 2007 Nov; 56(11):1564-71. PubMed ID: 17339237
[TBL] [Abstract][Full Text] [Related]
11. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
[TBL] [Abstract][Full Text] [Related]
12. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Ogino S; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS
Int J Cancer; 2008 Jun; 122(12):2767-73. PubMed ID: 18366060
[TBL] [Abstract][Full Text] [Related]
13. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer.
Nosho K; Shima K; Irahara N; Kure S; Baba Y; Kirkner GJ; Chen L; Gokhale S; Hazra A; Spiegelman D; Giovannucci EL; Jaenisch R; Fuchs CS; Ogino S
Clin Cancer Res; 2009 Jun; 15(11):3663-71. PubMed ID: 19470733
[TBL] [Abstract][Full Text] [Related]
14. CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.
Vedeld HM; Merok M; Jeanmougin M; Danielsen SA; Honne H; Presthus GK; Svindland A; Sjo OH; Hektoen M; Eknaes M; Nesbakken A; Lothe RA; Lind GE
Int J Cancer; 2017 Sep; 141(5):967-976. PubMed ID: 28542846
[TBL] [Abstract][Full Text] [Related]
15. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
[TBL] [Abstract][Full Text] [Related]
16. The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.
Cohen SA; Yu M; Baker K; Redman M; Wu C; Heinzerling TJ; Wirtz RM; Charalambous E; Pentheroudakis G; Kotoula V; Kalogeras KT; Fountzilas G; Grady WM
Clin Epigenetics; 2017; 9():46. PubMed ID: 28469732
[TBL] [Abstract][Full Text] [Related]
17. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A
Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836
[TBL] [Abstract][Full Text] [Related]
18. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
19. CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci.
Kawasaki T; Ohnishi M; Nosho K; Suemoto Y; Kirkner GJ; Meyerhardt JA; Fuchs CS; Ogino S
Mod Pathol; 2008 Mar; 21(3):245-55. PubMed ID: 18204436
[TBL] [Abstract][Full Text] [Related]
20. No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.
Jia M; Jansen L; Walter V; Tagscherer K; Roth W; Herpel E; Kloor M; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
Br J Cancer; 2016 Nov; 115(11):1359-1366. PubMed ID: 27811854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]